DCAT Value Chain Insights

The essential resource for the global bio/pharmaceutical manufacturing value chain from the Drug, Chemical & Associated Technologies Association (DCAT).

[DCAT Value Chain Insights @DCATvci]

It’s been a pleasure sharing industry news to our DCAT Members via the #DCATValueChainInsights Twitter account. After careful consideration we've decided to say farewell here and continue to update our Members on LinkedIn. Stay up to date & follow us here: https://t.co/O8VUkWCSEg

[DCAT @dcatorg]

A new episode of the #DCAT #ValueChainInsights podcast is available! Listen to hear a roundtable discussion by experts from #VetterPharma and #CordenPharma. Thanks to our #podcast sponsor, #VetterPharma! Subscribe on Apple, Google, or Spotify to listen: https://t.co/FmWiANkpsd

[DCAT Value Chain Insights @DCATvci]

Have you caught the latest episode of the #DCAT #ValueChainInsights podcast? Thanks again to our sponsor #VetterPharma!

[DCAT @dcatorg]

A new episode of the #DCAT #ValueChainInsights podcast is now available! Thank you to our #podcast sponsor, @vetterpharma! Subscribe to our channel on Apple, Google, or Spotify to listen to all of our podcast episodes. https://t.co/3SscneTCCw

[DCAT Value Chain Insights @DCATvci]

What have been some of the highs & lows thus far in 2023 from the large bio/pharma companies and what may be expected for the rest of the year? #DCAT #ValueChainInsights sums up the latest developments. https://t.co/1JH3Pj7TBq

[DCAT Value Chain Insights @DCATvci]

#SupplierNews: @Merck & Co. and @Ginkgo Bioworks have entered a $490-million biologic manufacturing pact; @AGCBiologics has completed an expansion at its Milan Cell & Gene Center of Excellence production site. Read more at #DCAT #TopIndustryNews https://t.co/1JH3Pj7TBq

[DCAT Value Chain Insights @DCATvci]

Members of Congress are calling for action to prevent drug shortages in light of issues facing pharma manufacturers, distributors & dispensers as they work to bring the drug supply chain into compliance with requirements. #DCAT #ValueChainInsights https://t.co/YkzVpKQ7JK

[DCAT Value Chain Insights @DCATvci]

The House Energy and Commerce Committee has issued a discussion draft with policy proposals to address drug shortages in the US. What is in the proposal? #DCAT #ValueChainInsights https://t.co/Uguh6G2gX0

[DCAT Value Chain Insights @DCATvci]

#SupplierNews: #Roquette has agreed to acquire #Qualicaps, a manufacturer of hard capsules and processing equipment for oral dosage forms; #BoraPharmaceuticals has opened a ophthalmic products mfg facility in Taiwan. Read more at #DCAT #TopIndustryNews https://t.co/upTMBaoiMb

[DCAT Value Chain Insights @DCATvci]

What are the top 10 drug-development deals (mergers & acquisitions) between large bio/pharma companies & smaller companies thus far in 2023? Which smaller companies have been the targets of large companies & in what product areas? #DCAT #ValueChainInsights https://t.co/libQsXLyLp

[DCAT Value Chain Insights @DCATvci]

Injectable drugs are an increasingly important part of the bio/pharma market. What are key trends and technological developments for injectable drugs, including drug-device technology? #DCAT #ValueChainInsights looks at the latest. https://t.co/vXn6mW9WvA

[DCAT Value Chain Insights @DCATvci]

#SupplierNews: #Axplora has installed a new cGMP pilot unit for flow chemistry at its Germany, site; @AlmacGroup has opened a new GMP warehouse and dispatch hub at its global headquarters in the UK. Read more at #DCAT #TopIndustryNews https://t.co/JiyFkxBlur

[DCAT Value Chain Insights @DCATvci]

The European Medicines Agency published a draft reflection paper seeking input from the bio/pharma industry & stakeholders on the use of artificial intelligence in drug development & the product lifecycle, including manufacturing. #DCAT #ValueChainInsights https://t.co/y32zaOcZSP

[DCAT Value Chain Insights @DCATvci]

The bio/pharma industry is urging FDA to postpone its Oct. 2023 deadline for testing for novel nitrosamine impurities in drugs, providing feedback in response to FDA’s call for input on how it should regulate these impurities. #DCAT #ValueChainInsights https://t.co/t5HTgfQ7t4

[DCAT Value Chain Insights @DCATvci]

#WuXiSTA has launched a high-potency sterile injectable mfg line at its site in China; @seqens_group is in talks with Novartis for the potential acquisition of Novartis’ CELLforCURE, a CDMO of cell & gene therapies. Read more at #DCAT #TopIndustryNews https://t.co/rQaZhm1vHP

[DCAT Value Chain Insights @DCATvci]

The US Federal Trade Commission & US Department of Justice issued draft guidelines outlining their review of mergers & acquisitions to determine compliance with federal antitrust laws. Will the mega-deal become a deal of the past? #DCAT #ValueChainInsights https://t.co/wJmd1zOPFT

[DCAT Value Chain Insights @DCATvci]

The US gov't has issued updated guidance for its drug-pricing negotiation plan, allowing negotiation of drug prices under Medicare. It follows opposition from the bio/pharma industry challenging the constitutionality of the plan. #DCAT #ValueChainInsights https://t.co/88HJRzgKXo

[DCAT Value Chain Insights @DCATvci]

#SupplierNews: #SamsungBiologics and @Novartis have formed a multi-million dollar biomanufacturing pact; @Evonik and @Heraeus are partnering to expand highly potent active pharmaceutical ingredient capabilities. Read more at #DCAT #TopIndustryNews https://t.co/Og4Iigh08m

[DCAT Value Chain Insights @DCATvci]

Driven by growth in the oncology drug sector, high-potency active pharmaceutical ingredient (HPAPI) manufacturing continues to be an active area of investment by CDMOs/CMOs. #DCAT #ValueChainInsights rounds up the latest expansions in HPAPI manufacturing. https://t.co/UwQvHdCqvk

[DCAT Value Chain Insights @DCATvci]

The Association for Accessible Medicines has issued a white paper that outlines recommendations to address shortages of generic drugs and ensure sustainable supply. #DCAT #ValueChainInsights https://t.co/ksaVD7bGWe

[DCAT Value Chain Insights @DCATvci]

What's the outlook for the global generic-drug market? A looming biologics patent cliff and double-digit growth for specialty generics bodes well for the market, but what is the outlook for other sectors? #DCAT #ValueChainInsights takes an inside look. https://t.co/MWzo0qSQyh